Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 11/20 | 0.65 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.42 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.42 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.41 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14034474 | 0.86 | CCR9 (0.53) | CCR9SMN1; SMN2 | |
| SCHEMBL11938257 | 0.86 | CCR9 (0.53) | CCR9SMN1; SMN2 | |
| SCHEMBL11936845 | 0.86 | CCR9 (0.49) | CCR9SMN1; SMN2KCNMA1 | |
| SCHEMBL12374819 | 0.81 | CCR9 (0.47) | CCR9SMN1; SMN2 | |
| SCHEMBL344540 | 0.79 | CCR9 (1.00) | CCR9 | |
| SCHEMBL11937175 | 0.78 | CCR9 (0.55) | CCR9SMN1; SMN2PPARGNR1H4 | |
| SCHEMBL11938267 | 0.78 | CCR9 (0.55) | CCR9SMN1; SMN2PPARGNR1H4 | |
| SCHEMBL11938278 | 0.77 | CCR9 (0.70) | CCR9 | |
| SCHEMBL10284611 | 0.76 | CCR9 (0.49) | CCR9KCNK2KCNK10SMN1; SMN2 | |
| SCHEMBL15906641 | 0.76 | CCR9 (0.64) | CCR9SMN1; SMN2KCNMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211896-B2 | Aryl sulfonamides | CHEMOCENTRYX, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20110021523-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021523-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | CCR9 1/4885KCNK2 2778/4885KCNK10 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.